Oct 2026· International Journal of Advanced Research in Science, Communication and Technology· pp. 283· 0 citations· 7 references
TL;DR
This research sought to design and assess a novel and non-invasive proposed model by utilizing the XGBoost classifier with Explainable Artificial Intelligence (XAI) for diagnosing liver cirrhosis and results have shown superiority for the proposed method compared with various machine learning models.
Abstract
Cirrhosis is a form of Chronic Liver Disease (CLD) resulting from sustained liver damage from several causes, including viral infection, autoimmune disorders, cholestatic and metabolic disease Non-Alcoholic Fatty Liver Disease (NAFLD) or heavy alcohol use. Testing for the presence of Liver Cirrhosis (LC) is one of the most critical diagnostics and prognostic assessments for patients. Detecting liver illness in its early stages is challenging as initial symptoms are often mild and difficult to diagnose. Cirrhosis may not present symptoms until an advanced stage, posing a challenge for identification and diagnosis. The lack of explanations for a complex model’s decision-making process creates clinician distrust by concealing the reasoning behind its choices. This research sought to design and assess a novel and non-invasive proposed model by utilizing the XGBoost classifier with Explainable Artificial Intelligence (XAI) for diagnosing liver cirrhosis. In this work XAI framework enhances transparency in complex models, offering valuable insights into decision-making, thereby guiding treatment strategies, and improving cirrhosis diagnosis. The experimental results have shown superiority for the proposed method compared with various machine learning models. The proposed method has achieved significantly 91.19% using XGBoost for cirrhosis dataset with K-fold validation(K=10) approach.
Recent advances in AI technology regarding various clinical aspects of liver cirrhosis and portal hypertension are discussed, including the diagnosis of cirrhosis and clinically significant portal hypertension, detection and prediction of major cirrhosis-related complications, and assessing the prognosis.
Chia-Fu Liu, Chien-Lin Chang, Ching-Chih Chang et al.· Journal of the Chinese Medic...· 0 citations
Chronic liver diseases (CLDs) frequently progress silently to advanced fibrosis or cirrhosis, yet existing predictive models have largely been developed for patients with clearly defined etiologies. Here, we asked whether a noninvasive machine‐learning model based on routine clinical variables and liver stiffness measu...
Ye Yang, Yi-Rui Hu, Ting Wei et al.· MedComm· 0 citations
Background: Autoimmune hepatitis (AIH) is a chronic immune-mediated liver disease that may progress to cirrhosis. This study aimed to develop and externally validate interpretable machine-learning models for the classification of prevalent cirrhosis in patients with AIH. Methods: The development cohort included 55 pati...
N. Ashimova, S. Abzaliyeva, Araylym Maldanova et al.· Biomedicines· 0 citations
Introduction Early identification of cirrhosis among patients with hepatitis is important for timely risk stratification and clinical management, yet conventional non-invasive scores such as the fibrosis-4 index (FIB-4) and the aspartate aminotransferase-to-platelet ratio index (APRI) may provide limited discrimination...
Qin Yang, Xue-Rui Hu, Shi-Hong Yu et al.· Frontiers in Genetics· 0 citations
Introduction and Objectives: Steatotic liver disease (SLD) is a leading cause of liver disease worldwide. Itsstratified into metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction and alcohol-associated liver disease (MetALD), and alcohol-associated liver disease (ALD) based on self-rep...
Mangesh Pagadala, Talal Khurshid, Wan-Yu Zhang et al.· Digestive and Liver Disease· 2 citations
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is the most common chronic liver disease around the world, affecting 33.6% of the adult population (95% CI: 28.1%–39.5%; I2 = 99.9%), or roughly one in three. The extent of the liver damage is...
M. Sujana, G. Vivekananda· Frontiers in Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.